Add BrightSurf on Google Email

Thomas Jefferson University


In initial gene therapy trial, Jefferson scientists report successful gene transfer in Canavan disease

Researchers at Jefferson Medical College successfully introduced a therapeutic gene into the brain of two children with Canavan disease, showing decreased NAA concentration and increased myelin. The gene transfer demonstrated positive neurological improvements in the patients, offering hope for future use of gene therapy for brain dise...

SourceThomas Jefferson University·JournalAnnals of Neurology·DateJul 30, 2000

Jefferson researchers find that by blocking growth factor, diabetic kidney disease can be prevented in mice

A study by Jefferson researchers found that blocking the transforming growth factor-beta (TGF-beta) protein can prevent diabetic kidney disease in mice. The antibody treatment prevented kidney scarring and renal failure, offering hope for a new treatment option for humans with type 2 diabetes.

SourceThomas Jefferson University·JournalProceedings of the National Academy of Sciences·DateJul 2, 2000

Mutations identified in gene causing blindness, early heart attacks

Molecular geneticists have characterized gene mutations in families with pseudoxanthoma elasticum (PXE), a rare inherited disorder that can lead to blindness, early heart attacks, and cardiovascular disease. The study provides the basis for DNA-based carrier detection, prenatal testing, and improved diagnosis of the condition.

SourceThomas Jefferson University·JournalProceedings of the National Academy of Sciences·DateMay 14, 2000

International group of breast cancer specialists agrees on treatment options for controversial early stage cancer

The international Consensus Conference Committee outlines treatment options for DCIS to determine the appropriate treatment for each patient. The committee recommends treating women with DCIS with breast conservation through lumpectomy or lumpectomy along with radiation therapy, while mastectomy may still be an option.

SourceThomas Jefferson University·JournalCancer·DateFeb 13, 2000

Jefferson scientists show drug is effective against a Hepatitis C Virus model in the laboratory

Researchers at Thomas Jefferson University and Oxford University have found a promising drug against the hepatitis C virus (HCV), called N-nonyl-DNJ, which inhibits the activity of an important cellular enzyme, glucosidase. This drug may sidestep resistant viruses, a major problem with current treatments.

SourceThomas Jefferson University·JournalProceedings of the National Academy of Sciences·DateOct 11, 1999

Jefferson researchers find access to new methods of HIV prevention for pregnant women and newborns may depend on where they were receiving care

Researchers found that HIV-infected pregnant women receiving care at specialized centers or state-funded sites were more likely to receive antiretroviral therapy, reducing transmission by up to two-thirds. The study highlights the importance of access to quality medical care in preventing mother-to-newborn transmission of AIDS.

SourceThomas Jefferson University·JournalAnnals of Internal Medicine·DateJun 15, 1999

Jefferson Researchers Report First Evidence Of Radiation Therapy Preventing Prostate Cancer Patients From Dying

Researchers at Thomas Jefferson University have found that radiation therapy helps patients with localized prostate cancer live longer. After examining the results of 1560 patients who received radiation therapy alone for prostate cancer, they discovered that those with high-risk disease benefited the most from higher doses of radiation.

Jefferson Scientists Suppress Tumor Growth In Animals, Aiming At Gene Therapy

Scientists at Thomas Jefferson University have demonstrated that a normally protective anticancer gene can block tumors from growing. Led by Dr. Antonio Giordano, they found that the damaged version of the gene, pRb2/p130, suppresses tumor growth in animal models, paving the way for gene therapy to treat lung cancer and other cancers.

SourceThomas Jefferson University·JournalJNCI Journal of the National Cancer Institute·DateOct 6, 1998